Patients with acute coronary syndrome should start a statin while still in hospital

Heart

Volumn 88, Issue 1, 2002, Pages 5-6

  Isles, Chris G ^a  

^a DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; STATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HUMAN; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 0036085584     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.88.1.5     Document Type: Short Survey

References (18)

1. Use of statins in the secondary prevention of coronary heart disease: Is treatment equitable?
2. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes
3. Age, sex and practice variations in the use of statins in general practice in England and Wales
4. Secondary prevention in 24,431 patients with coronary heart disease: Survey in primary care
5. Use of lipid lowering medications at discharge in patients with acute myocardial infarction: Data from the national registry of myocardial infarction 3
6. Clinical reality of coronary prevention guidelines: A comparison of EURO-ASPIRE I and II in 9 countries
7. Cost effectiveness of HMG CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
8. Randomised trials of secondary prevention programmes in coronary heart disease: A systematic review
9. Secondary prevention of CHD and the National Service Framework: Barriers to implementation
10. Improved treatment of coronary heart disease by implementation of a cardiac hospitalisation atherosclerosis management programme (CHAMP)
11. Usefulness of in hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reducing mortality
12. Effect of lipid lowering therapy on early mortality after acute coronary syndromes: An observational study
13. Early statin treatment following acute myocardial infarction and one year survival
14. The effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes. The MIRACL study: A randomised controlled trial
15. Beneficial effects of pravastatin (± cholestyramine/niacin) initiated immediately after a coronary event. The randomised lipid coronary artery disease (LCAD) study
16. In hospital initiation of lipid lowering therapy for patients with coronary heart disease: The time is now